HD1916 trial: chemically made semaglutide

A Phase III trial in China found that HD1916, a chemically synthesized version of semaglutide, met its prespecified equivalence criterion against Wegovy for average body-weight change after 44 weeks in adults with obesity and no diabetes^[1]. This is a head-to-head study of a named investigational product, not evidence that every product sold as semaglutide is equivalent to a reference medicine. It also does not change the regulatory status of semaglutide products in any country.

The paper reports 462 participants across 30 centres, split evenly between HD1916 and reference semaglutide. Mean body weight fell 13.1% in the HD1916 group and 14.4% in the reference group. The estimated between-group difference was 1.35 percentage points, and its 95% confidence interval stayed inside the protocol's equivalence margin. That is the central result. The study asks whether these two trial products produced sufficiently similar results under its own design. It does not establish a personal treatment choice or a general rule about chemically synthesized products.

What HD1916 is and what the trial tested

HD1916 is described in the paper as chemically synthesized semaglutide injection. The authors compared it with the reference product Wegovy in an open-label, active-controlled Phase III trial. Participants were Chinese adults aged 18 to 75 years who had obesity, defined in the protocol as a body-mass index of at least 28 kg/m2, and did not have diabetes. The trial administered once-weekly subcutaneous treatment for 44 weeks. That schedule describes the research protocol; it is not dosing guidance for readers.

The primary endpoint was percentage change in body weight from baseline to week 44. The protocol set an equivalence margin of plus or minus 4.16 percentage points for the difference between groups. It also examined the proportions of participants reaching at least 5% and at least 10% weight loss, along with change in waist circumference^[2]. Those secondary measures were reported as comparable between groups, but the primary endpoint and its confidence interval are the most useful way to read the equivalence finding.

What the weight-loss result means

Equivalence trials answer a different question from placebo-controlled efficacy trials. A placebo comparison asks whether a treatment outperformed no active study drug under the trial conditions. This study instead tested whether HD1916 and the designated reference semaglutide produced results close enough to satisfy a margin chosen in advance. The reported confidence interval for the difference was minus 0.02 to 2.72 percentage points. Because that interval remained within the stated margin, the authors concluded that the products were therapeutically equivalent for the primary endpoint.

That conclusion has limits. It applies to the population studied, the 44-week follow-up period, the products used in the trial and the outcome specified in the protocol. It is not a finding that one formulation works better than the other. The average changes also do not predict what any one person will experience. Baseline health, tolerability, adherence, access to follow-up and the broader treatment plan can all matter, none of which can be reduced to a single trial average.

What the safety data showed

Any-grade treatment-emergent adverse events occurred in 86.5% of participants receiving HD1916 and 89.2% of participants receiving reference semaglutide. The abstract says most events were Grade 1 or 2 and describes the safety profiles as comparable

Those figures need careful context. They describe events recorded in this particular controlled trial, not a complete estimate of long-term safety or a guarantee about a product outside the trial. The published record does not turn the trial into an instruction manual. Readers looking for broader background on the medicine can use our semaglutide safety overview, while decisions about symptoms, medical history or treatment changes belong with a qualified clinician.

Why chemical synthesis does not settle the product question

The phrase chemically synthesized describes how the investigational semaglutide in this paper was made. It does not, by itself, show that an unrelated product has the same identity, purity, dose delivery, manufacturing controls or regulatory authorization as a reference medicine. The trial supports a narrow comparison between HD1916 and Wegovy under defined conditions. It should not be used to validate unverified online products, compounded preparations or materials sold for research use.

That distinction matters because semaglutide is a prescription medicine in the settings covered by PeptideMethods. Our main semaglutide guide explains the medicine's evidence base and regulatory context. A trial result about HD1916 does not replace a regulator's product-specific review, and it does not establish that products sharing a molecule name are interchangeable.

What we do not yet know

The PubMed record is an online-ahead-of-print report dated 7 October 2026. It gives no long-term follow-up beyond 44 weeks, and the abstract cannot answer questions about durability after treatment stops, rare adverse events, outcomes in people with diabetes, or results in populations outside the enrolled Chinese adults. It also does not provide a basis for comparing HD1916 with every other semaglutide presentation or with other GLP-1 medicines.

Regulatory decisions, manufacturing oversight and product labelling are separate questions. The paper does not report that HD1916 has been authorized for a particular use, and this article makes no claim that it has. For now, the evidence is best read as a specific Phase III equivalence result. It adds information about one investigational product, while leaving practical access and longer-term outcomes unresolved.

HD1916 met the trial's equivalence standard

HD1916 produced a mean 13.1% body-weight reduction at week 44, compared with 14.4% for reference semaglutide in this 462-person trial. The confidence interval for the difference met the study's predefined equivalence standard. That is meaningful clinical-trial evidence for the tested products, but it is not a universal equivalence claim and it is not personal medical advice. Anyone considering semaglutide should discuss the appropriate approved product and its risks with a clinician who knows their circumstances.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.